| Prev Close | 508.31 |
| Day Low/High | 509.20 / 518.92 |
| 52 Wk Low/High | 328.12 / 664.64 |
Regeneron Pharmaceuticals, Inc. (REGN)
514.05
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 106.71B |
| Market Cap | 54.24B |
| P/E Ratio | 18.63 |
| Div & Yield | N.A. (N.A) |
Amgen Shows a Bullish Breakout
There is more upside to come for this stock.
Bullish Momentum for Regeneron
Volatility has calmed down, and there are bullish signs.
Cramer: Here's the Reason for Allergan's Remarkable Run
Static doesn't work in this industry. Pipelines work.
Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short
The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.
Jim Cramer Sees Buying Opportunities in Praluent Patent Suit
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
Use Regeneron's Current Weakness to Go Long
Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.
Prepare for Biotech Action Aplenty Today
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
Regeneron Cholesterol-Lowering Drug Banned From U.S. Market
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
Ophthtech Shares Plunge as Drug Fails in Late Stage Trial
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Cramer: With Trump, Everything's a Negotiation
Just ask the drug companies or Boeing.
Cramer: We Are in Stage 2 of the Trump Love Affair With Business
Hillary isn't the only one who seems to favor workers over capital. Trump does, too.
Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
Markets Await October Jobs Report Friday
The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.
Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.
FDA Puts Hold on Regeneron Pain-Drug Study
Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.
Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide
On days like this, the money just keeps sloshing around.
Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
Cramer: Here's What to Embrace and What to Shun
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
Amgen and Regeneron Expanding Anti-Cancer Research
The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.
Cramer: What Are You Thinking? It Should Be Long Term
That may be the best way to get through the notorious month of August.
Jim Cramer: I’m Looking at the Biotechs
Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.
Regeneron Is Regenerating Lost Profits
Investors should risk below $380 for now.
Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?
Biotech, restaurants and retail have been left for dead but are showing signs of life today.
Regeneron Tries to Recover From Lows
Prices pop today, but is this a reversal?
Regeneron May Cure the Market Blues
A potentially bullish pattern is setting up.
How to Trade Regeneron's Pullback
Aggressive traders can go long REGN on the first up day.
